BRIEF: Airdoc Tech approved for H-share full circulation
Beijing Airdoc Technology Co. Ltd. (2251.HK) announced on Monday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 50.15 million of its domestic shares into H-shares that can be publicly traded in Hong Kong. The conversion involves company stock held by 26 shareholders.
Airdoc was founded in 2015 as a provider of ophthalmic imaging solutions. Last July it announced the development of its Wanyu Medical Large Model, expanding its services from single-image diagnostics to general medical Q&A and health management. This February, it upgraded the Wanyu model and integrated it with the DeepSeek R1 model.
Airdoc’s revenue fell 23.3% year-on-year to 156 million yuan ($21 million) last year, while its net loss widened significantly from 133 million yuan in 2023 to 255 million yuan last year. The company’s shares have plunged 83.22% since their listing in November 2021, including a 7.95% decline this year.
By Lee Shih Ta
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
RELATED ARTICLES
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK -
BRIEF: Voicecomm approved for full H-share circulation
2495.HK
-
BRIEF: Qyuns Therapeutics secures CSRC approval for full H-share circulation
2509.HK
-
BRIEF: Surging Laopu Gold to boost share float after full circulation approval
6181.HK
-
BRIEF: Rimag Group secures CSRC approval for full circulation of H-Shares
2522.HK
- BRIEF: Shein London IPO approved by British financial regulator
- BRIEF: Yimutian approved by China for Nasdaq IPO
